000154327 001__ 154327
000154327 005__ 20240227115125.0
000154327 0247_ $$2doi$$a10.1002/mds.28300
000154327 0247_ $$2pmid$$apmid:33006791
000154327 0247_ $$2ISSN$$a0885-3185
000154327 0247_ $$2ISSN$$a1531-8257
000154327 0247_ $$2altmetric$$aaltmetric:91713096
000154327 037__ $$aDZNE-2021-00181
000154327 041__ $$aEnglish
000154327 082__ $$a610
000154327 1001_ $$aAl Shweiki, Mhd Rami$$b0
000154327 245__ $$aCerebrospinal Fluid Levels of Prodynorphin-Derived Peptides are Decreased in Huntington's Disease.
000154327 260__ $$aNew York, NY$$bWiley$$c2021
000154327 3367_ $$2DRIVER$$aarticle
000154327 3367_ $$2DataCite$$aOutput Types/Journal article
000154327 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1708965330_5083
000154327 3367_ $$2BibTeX$$aARTICLE
000154327 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000154327 3367_ $$00$$2EndNote$$aJournal Article
000154327 500__ $$aISSN 1531-8257 not unique: **3 hits**.
000154327 520__ $$aHuntington's disease (HD) is a devastating neurodegenerative disorder characterized by a selective loss of striatal medium spiny projection neurons (MSNs). Prodynorphin (PDYN) is enriched in a subpopulation of striatal MSNs. Postmortem brains of HD patients and rodent models have been demonstrated to have reduced levels of PDYN transcripts and the neuropeptide dynorphin.Given the unmet need for novel pharmacodynamic HD biomarkers in the context of experimental huntingtin (htt)-lowering therapies, we investigated the levels of PDYN-derived peptides and neurofilament light (NfL) chain in the cerebrospinal fluid (CSF) from HD patients (n = 16), matched controls (n = 55), and patients with other neurodegenerative disorders (n = 70).PDYN-derived peptide levels were found to be substantially decreased in HD patients (P < 0.0001 in comparison to controls), whereas the NfL levels were elevated in all neurodegenerative disorders.Our study suggests decreased PDYN-derived peptide levels in the CSF as a more specific biomarker for HD in comparison to NfL. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
000154327 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000154327 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000154327 650_7 $$2Other$$aneurofilaments; prodynorphin; biomarker; Huntingtonʼs disease; frontotemporal dementia
000154327 650_2 $$2MeSH$$aCorpus Striatum: metabolism
000154327 650_2 $$2MeSH$$aEnkephalins
000154327 650_2 $$2MeSH$$aHumans
000154327 650_2 $$2MeSH$$aHuntingtin Protein
000154327 650_2 $$2MeSH$$aHuntington Disease
000154327 650_2 $$2MeSH$$aNeurofilament Proteins
000154327 650_2 $$2MeSH$$aPeptides
000154327 650_2 $$2MeSH$$aProtein Precursors
000154327 7001_ $$aOeckl, Patrick$$b1
000154327 7001_ $$aPachollek, Adrian$$b2
000154327 7001_ $$aSteinacker, Petra$$b3
000154327 7001_ $$aBarschke, Peggy$$b4
000154327 7001_ $$aHalbgebauer, Steffen$$b5
000154327 7001_ $$aAnderl-Straub, Sarah$$b6
000154327 7001_ $$aLewerenz, Jan$$b7
000154327 7001_ $$0P:(DE-2719)2812633$$aLudolph, Albert C$$b8$$udzne
000154327 7001_ $$aBernhard Landwehrmeyer, Georg$$b9
000154327 7001_ $$0P:(DE-HGF)0$$aOtto, Markus$$b10$$eCorresponding author
000154327 773__ $$0PERI:(DE-600)2041249-6$$a10.1002/mds.28300$$gVol. 36, no. 2, p. 492 - 497$$n2$$p492 - 497$$tMovement disorders$$v36$$x1531-8257$$y2021
000154327 8564_ $$uhttps://pub.dzne.de/record/154327/files/DZNE-2021-00181.pdf$$yOpenAccess
000154327 8564_ $$uhttps://pub.dzne.de/record/154327/files/DZNE-2021-00181.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000154327 909CO $$ooai:pub.dzne.de:154327$$pVDB$$popen_access$$pdnbdelivery$$pdriver$$popenaire
000154327 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812633$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000154327 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000154327 9132_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000154327 9141_ $$y2021
000154327 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-30
000154327 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000154327 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2021-01-30$$wger
000154327 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-30
000154327 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000154327 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-11$$wger
000154327 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOVEMENT DISORD : 2021$$d2022-11-11
000154327 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-11
000154327 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-11
000154327 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-11
000154327 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-11
000154327 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-11
000154327 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-11
000154327 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-11
000154327 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-11
000154327 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bMOVEMENT DISORD : 2021$$d2022-11-11
000154327 9201_ $$0I:(DE-2719)5000077$$kClinical Study Center Ulm$$lClinical Study Center Ulm$$x0
000154327 980__ $$ajournal
000154327 980__ $$aVDB
000154327 980__ $$aI:(DE-2719)5000077
000154327 980__ $$aUNRESTRICTED
000154327 9801_ $$aFullTexts